RATIONALE, DEVELOPMENT AND IMPLEMENTATION OF THE FUNCTIONAL-ORGANIZATIONAL MODEL FOR IMPROVEMENT OF SECONDARY PREVENTION OF ACTINIC KERATOSIS
ARTICLE PDF (Українська)

Keywords

actinic keratosis, secondary prevention, functional-organizational model

How to Cite

ОshyvalovaО. О., & Zyukov, O. L. (2019). RATIONALE, DEVELOPMENT AND IMPLEMENTATION OF THE FUNCTIONAL-ORGANIZATIONAL MODEL FOR IMPROVEMENT OF SECONDARY PREVENTION OF ACTINIC KERATOSIS. Clinical and Preventive Medicine, (3-4), 31-40. https://doi.org/10.31612/2616-4868.3(9).2019.04

Abstract

It is known that effective prevention of skin cancer is to identify individuals with a high level of risk factors for skin cancer, timely diagnosis and active treatment of precancerous skin lesions. Among the diseases that pose an increased risk of squamous cell carcinoma are actinic keratosis. Thus, effective prevention of actinic keratosis is one of the crucial factors in justifying cost minimization and improving patients' quality of life.

Aim – to substantiate the improvement of secondary prevention of actinic keratosis by developing a functional-organizational model based on a process approach.

Material and methods.The methods of system and process approach, system and content analysis are applied in the research; medical-statistical, descriptive modeling. Statistical processing of material using EZR v. 1.35.

Results. The proposed model envisages a number of structural elements and functions inherent in them, from the provision of health services at the level of a health care facility to communicative, informational-analytical, educational-methodological and scientific, resource and regulatory support at the territorial and national levels of government. The advantages of the proposed model include its justification based on the results of research, international developments, as well as current regulatory documents, medical standards. The implementation of the model will allow the healthcare provider to select and apply the necessary set of preventive measures in accordance with the medical-technological standards of medical care. The values ​​of the coefficients of variation for all the distinguished advantages of the model, which were evaluated during the examination, did not exceed 10.0%, which indicates a low degree of variability and unanimity of expert estimates.

Conclusions. The proposed functional and organizational model for improving the secondary prevention of actinic keratosis is in line with the principles of comprehensiveness and continuity of medical care and provides patients with quality and affordable medical care while optimizing available resources.

https://doi.org/10.31612/2616-4868.3(9).2019.04
ARTICLE PDF (Українська)

References

Pro zatverdzhennia normatyviv nadannia medychnoi dopomohy ta pokaznykiv yakosti medychnoi dopomohy: Nakaz MOZ Ukrainy vid 28.12.2002r. №507 iz zminamy vid 16.07.2014r. Availelable at: http://zakon.rada. gov.ua/rada/show/ru/v0507282-02

Pro udoskonalennia dermatovenerolohichnoi dopomohy naselenniu Ukrainy Nakaz MOZ Ukrainy 07.06.2004r. №286 iz zminamy vid 04.07.2016r. Availelable at: https://zakon.rada.gov.ua/rada/show/v0286282-04

Pro zatverdzhennia protokoliv nadannia medychnoi dopomohy a spetsialnistiu «onkolohiia»: Nakaz MOZ Ukrainy vid 17.09.2007r. №554. Availelable at: http://mozdocs. kiev.ua/view.php?id=9118

Oshyvalova O.O., Kaliuzhna L.D., Shponka I.S., Poslavska O.V. (2019). Imunohistokhimichni osoblyvosti vohnyshch aktynichnoho keratozu. Morfolohiia. Tom 13, №3. S.7-21. https://sites.google.com/a/dsma.dp.ua/confmorphology/home

Oshyvalova O. (2019). Efektyvnist vprovadzhennia lokalnoho protokolu medychnoi dopomohy khvorym na epidermalni dysplazii shkiry v bahatoprofilnomu medychnomu zakladi. Visnyk problem biolohii i medytsyny, 1, 1 (148), 307-313. Availelable at: https://vpbm.com.ua/ua/vyipusk-1-tom-1-(148),-2019/11975

Oshyvalova O. (2019). Klinichnyi profil patsiienta z poiednanym perebihom epidermalnykh dysplazii shkiry. Dermatolohiia ta venerolohiia, 1 (83), 33-36. Availelable at: http://idvamnu.com.ua/wp-content/uploads/2019/04/2019_01

Actinic Keratosis Clinical Practice Guidelines: An Appraisal of Quality (2015). USA. Availelable at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588356/

Actinic Keratosis: Rationale and Management»/Australia (2014). Availelable at: https://www. ncbi.nlm.nih.gov/pmc/articles/PMC4588356/

Аctinic keratoses - also known as solar keratoses (2013). United Kingdom. Availelable at: http://www.bad.org.uk/shared/get-file.ashx?id=1974&itemtype=document.

Augustin M., Tu J. H., Knudsen K. M., Erntoft S., Larsson T., Hanke C. W. (2015). Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am. Acad. Dermatol., 72, 816–821. Availelable at: https://www.ncbi.nlm.nih.gov/ pubmed/25770879

Australian Cancer Incidence and Mortality (ACIM) books: Non-melanoma skin cancer, all types (2014). Australian Institute of Health and Welfare, Canberra. Availelable at: http://www.aihw.gov.au/acim-books.

Cancer Facts & Figures is an annual publication of the American Cancer Society (2018). Atlanta, Georgia. Availelable at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf

Cockerell C. J. (2000). Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol. 42 (1 Pt 2). 11 - 7. Availelable at: https://www.ncbi.nlm. nih.gov/pubmed/10607351

Criscione V. D., Weinstock M. A., Naylor M. F., Luque C., Eide M. J., Bingham S. F. (2009). Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer, 115(11), 2523–2530. Availelable at: https://www.ncbi.nlm.nih. gov/pubmed/19382202

Czarnecki D., Meehan C.J., Bruce F., Culjak G. (2002). The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg., 6, 207 - 209. Availelable at: https://www.ncbi.nlm.nih.gov/pubmed/11951126

Evidence and consensus based (S3) Guidelines for the Treatment of Actinic Keratosis International League of Dermatological Societies (ILDS) in cooperation with the European Dermatology Forum (EDF) (2015). Availelable at: https://www. ncbi.nlm.nih.gov/pubmed/26370093

Health system expenditure on cancer and other neoplasms in Australia: 2008-09 (2013). Cancer series no. 81. Cat. no. 78. Australian Institute of Health and Welfare., Canberra Availelable at: https://www.aihw.gov.au/reports/health-welfare-expenditure/health-system-expenditure-cancer-2008-09/contents/table-of-contents

Lebwohl M., Swanson N., Anderson L. L., Melgaard A., Xu Z., Berman B. (2012). Ingenol mebutate gel for actinic keratosis. N Engl J Med., 366, 1010–1019. https://www.ncbi.nlm.nih.gov/pubmed/22417254

Marks R., Rennie G., Selwood T. S. (1988). Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet, 1(8589), 795–797. Availelable at: https://www.ncbi.nlm.nih.gov/pubmed/2895318

National Cancer Registry of Ukraine: short description of the database as of January (2018). Availelable at: http://www.ncru.inf.ua/publications/index.htm

Noels E. C., Lugtenberg M., van Egmond S., Droger S. M., Buis P. A. J., Nijsten Т. (2019). Insight into the management of actinic keratosis: a qualitative interview study among general practitioners and dermatologists. British Journal of Dermatology, 181, 1, 96-104. Availelable at: https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.17818

Non-melanoma skin cancer: General practice consultations, hospitalisation and mortality (2008). Australian Institute of Health and Welfare, Canberra. Availelable at: https://www.aihw.gov.au/ reports/cancer/non-melanoma-skin-cancer/contents/table-of-contents

Oshyvalova O., Rossokha Z. Modern view on epidermal dysplasia carcinogenesis. Exp. Oncol. (2019), 41 (3), 216-223. Availelable at: http://exp-oncology.com.ua/article/13504/modern-view-on-epidermal-dysplasia-carcinogenesis

Oshyvalova O., Ziukov О., Gurianov V. Prognostic model of skin cancer risk assessment. Wiadomości Lekarskie (2019). LXXII, Nr 5, cz I, 817-822. Availelable at: http://wl.medlist.org/2019_05_18/

Ratushny V., Gober M. D., Hick R., Ridky T. W., Seykora J. T. (2012). From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest., 122(2), 464–472. Availelable at: https://www.ncbi.nlm.nih.gov/pubmed/22293185

Salasche S. J. (2000). Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol., 42(1 Pt 2), 4 - 7. Availelable at: https://www.ncbi.nlm.nih.gov/pubmed/10607349

Staples M. P, Elwood M., Burton R. C et al. Non-melanoma skin cancer in Australia: the 2002

national survey and trends since 1985 (2006). Med J Aust., 184 (1), 6-10. Availelable at: https://www.ncbi.nlm.nih.gov/pubmed/16398622

World Health Organisation (2018). Cancer. Accessed 2018. Availelable at: https://www.who.int/en/news-room/fact-sheets/detail/cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.